RxDoctor Payments Data

Steven Ross, DO

Family Medicine · Weatherford, TXNPI 1629077466

Payments from drug & device makers

$793in general payments, 2019–2025

Across 40 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$207
  • Pfizer$166
  • AbbVie$154
  • Novo Nordisk$48
  • Amarin Pharma, Inc.$38
  • E.r. Squibb & Sons, L.L.C.$34
  • plus $147 from 8 others

What the payments were for

  • Food & beverage$793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$793 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$171,572
Medicare patients
284
Services billed
2,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$67,204
EliquisApixaban29$34,557
JanuviaSitagliptin Phosphate33$34,209
XareltoRivaroxaban29$31,015
JardianceEmpagliflozin33$28,019
TradjentaLinagliptin17$16,668
TrulicityDulaglutide11$14,525
Valsartan153$4,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,582
Levothyroxine Sodium295$2,744
Metoprolol Succinate129$2,620
Potassium Chloride119$2,461
Gabapentin133$2,205
Pravastatin Sodium150$2,061
Atorvastatin Calcium185$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$67,20450 claims
Boehringer IngelheimJardiance, Tradjenta$24$44,68750 claims
PfizerEliquis$166$34,55729 claims
Johnson & JohnsonXarelto$15$31,01529 claims
Lilly USA, LLCTrulicity$207$14,52511 claims
AbbVieSynthroid$154$63317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Weatherford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →